Lexaria Bioscience Corp. - Common Stock (LEXX)
1.7700
-0.0500 (-2.75%)
Lexaria Bioscience Corp is a biotechnology company that focuses on the development of its proprietary drug delivery technology, which enhances the bioavailability of active pharmaceutical ingredients
The company's primary goal is to improve the efficacy and speed of absorption for various compounds, particularly those related to cannabis and nicotine. Through its innovative methods, Lexaria aims to revolutionize the way these substances are consumed, potentially leading to more effective therapeutic outcomes and improved user experiences in the market for both recreational and medicinal products.
Previous Close | 1.820 |
---|---|
Open | 1.830 |
Bid | 1.730 |
Ask | 1.820 |
Day's Range | 1.740 - 1.847 |
52 Week Range | 1.427 - 6.850 |
Volume | 48,535 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 234,852 |
News & Press Releases
Lexaria Releases Annual Letter from the CEO
KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQLEXX)NASDAQ:LEXXWNASDAQLEXXW)
Via ACCESS Newswire · January 30, 2025
Lexaria’s Human GLP-1 Study #5 Receives Independent Review Board Approval
Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format
Via ACCESSWIRE · January 15, 2025
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound®
Via ACCESSWIRE · January 14, 2025
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss
Via ACCESSWIRE · December 19, 2024
Lexaria Forms New Scientific Advisory Board
North American drug delivery development experts added to help guide Lexaria's strategic plans
Via ACCESSWIRE · December 18, 2024
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Dr. Gibson joining Lexaria's new scientific advisor board
Via ACCESSWIRE · December 17, 2024
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Positive results in recent animal study strongly support first-ever human investigation for DehydraTECH-liraglutide
Via ACCESSWIRE · December 9, 2024
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Semaglutide being investigated for applications in heart disease, Alzheimer's, liver disease, and more
Via ACCESSWIRE · November 26, 2024
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format
Via ACCESSWIRE · November 25, 2024
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) provided a strategic update on its efforts to leverage its DehydraTECH technology within the rapidly growing GLP-1 drug market, projected to surpass $100 billion annually. GLP-1 drugs, initially approved for diabetes and weight loss, are now being explored for broader applications, including cardiovascular, liver, and kidney diseases, as well as sleep apnea and neurodegenerative conditions. Lexaria is advancing research to enhance GLP-1 drug delivery to the brain, with data from its animal study on brain absorption expected by early 2025. The company aims to capitalize on the transformative potential of GLP-1 drugs by enabling expanded therapeutic benefits and improved efficacy through its proprietary technology.
Via Investor Brand Network · December 3, 2024
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) provided a strategic update on its efforts to leverage its DehydraTECH technology within the rapidly growing GLP-1 drug market, projected to surpass $100 billion annually. GLP-1 drugs, initially approved for diabetes and weight loss, are now being explored for broader applications, including cardiovascular, liver, and kidney diseases, as well as sleep apnea and neurodegenerative conditions. Lexaria is advancing research to enhance GLP-1 drug delivery to the brain, with data from its animal study on brain absorption expected by early 2025. The company aims to capitalize on the transformative potential of GLP-1 drugs by enabling expanded therapeutic benefits and improved efficacy through its proprietary technology.
Via CannabisNewsWire · December 3, 2024
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in both body weight-loss, by 11.53% and 10.65% respectively, and in blood sugar, by 11.13% and 3.35% respectively.
Via ACCESSWIRE · November 20, 2024
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules
Via ACCESSWIRE · November 14, 2024
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
DehydraTECH clinical test article manufacturing has been completed
Via ACCESSWIRE · November 13, 2024
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
DehydraTECH™ for GLP-1 being optimized for global pharmaceutical use
Via ACCESSWIRE · November 7, 2024
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups
Via TheNewswire.com · October 24, 2024
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups
Via ACCESSWIRE · October 24, 2024
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups
Via TheNewswire.com · October 22, 2024
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups
Via ACCESSWIRE · October 22, 2024
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Kelowna, British Columbia – October 16, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the “Stockholder Approval Date”) and will expire five years from the Stockholder Approval Date.
Via TheNewswire.com · October 16, 2024
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
KELOWNA, BC / ACCESSWIRE / October 16, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants (the "Stockholder Approval Date") and will expire five years from the Stockholder Approval Date.
Via ACCESSWIRE · October 16, 2024
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format
Via ACCESSWIRE · October 9, 2024
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Lexaria Bioscience Corp. (NASDAQLEXX)NASDAQ:LEXXWNASDAQLEXXW)
Via ACCESSWIRE · October 15, 2024
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Wednesday morning that dosing has begun for human pilot study #3. The study aims to investigate a DehydraTECH-processed version of Zepbound(R) (tirzepatide), the dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in oral dose format.
Via Investor Brand Network · October 9, 2024